VPM1002 booster effect "VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical

nehmen das vor Ort auf, möchten es unterstützen und stärken. Auch in der MHH sind Menschen an und mit COVID-19 gestorben. Ihrer gedenken wir mit dieser Schweigeminute. Unser aufrichtiges Mitgefühl gilt ihren

published the world's first paper on the new XBB.1.5-based vaccine from Biontech. As part of the "COVID-19 Contact (CoCo)" study at the MHH, 53 MHH employees who received the vaccine were examined. Their

implementation of SORMAS as well as his great personal commitment to public information during the COVID-19 pandemic were contributions of particularly high societal value," says Prof Dirk Heinz, Scientific

deteriorates. But SARS-CoV-2 also attacks the heart muscle. "In up to ten per cent of severely affected COVID-19 sufferers, new heart failure that was not present before the infection can occur within a year

clinically - for example, to provide oxygen to patients in intensive care units who are severely ill with COVID-19. "So far, however, we have only been able to bridge lung function with ECMO for a certain period

with our research focus 'Infection and Immunity' and received many research funds for SARS CoV2 and COVID19 research.101.4 million euros is considerable for a divisional university like the MHH, the only

research the virus and the disease, and to overcome the pandemic." The university's well-connected COVID 19-/SARS-CoV-2 research alone has raised more than 30 million euros in additional external funding

more than a dozen highly innovative immunotherapeutics are now on the way to market and the first Covid-19 vaccine has been approved. Prof. Huber has been impressively active as a reviewer and officer in